Morphosys/Incyte’s Monjuvi Wins Early US FDA Approval In Second-Line DLBCL
MAb’s CAR-T Like Efficacy Seen Giving Wide Adoption
Monjuvi’s good efficacy and safety profile should enable its broad adoption in the second line DLBCL space and help it compete well against rival CAR-T therapies, analysts said.
You may also be interested in...
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
The latest US FDA approvals and actions from the Pink Sheet’s US FDA Performance Tracker.
The first-in-class anti-CD79b antibody-drug conjugate received a swift accelerated approval by the US FDA based on the results of a Phase Ib/II trial, for the same setting as CAR-T agents.